Background: Unknown primary tumors are highly malignant diseases which portend a dire prognosis. We designed a prospective high dose-intensity policy with the aim of improving the results obtained with conventional chemotherapy.
Introduction
Carcinomas of unknown primary site comprise a group of heterogeneous tumors that share the unique clinical characteristic of metastatic disease with no identifiable origin at the time of therapy. The primary site is supposed to either have a slow growth or even become involute. Despite advances in tumor imaging and pathology, patients with metastatic carcinomas from an unidentified primary site still account for 5%-10% of all cancer patients [1] . Outcome is poor, with a median survival of about 6 to 11 months. The optimal chemotherapy remains to be determined, and the benefits of chemotherapy over those of best supportive care are still unclear [2] . Reports of durable responses with platinum-based chemotherapy have been reported only in the subset of patients with poorly differentiated carcinomas, with 10%-20% of longterm survivors [3] .
In recent years, the delivery of increased doses or increased dose intensities of cytotoxic agents has been advanced with the objective of improving the disappointing results observed in metastatic solid tumors with conventional-dose chemotherapy. Such an approach has been promoted by new techniques of hematopoietic stem-cell support and advances in the knowledge of hematopoiesis. The use of hematopoietic growth factors along with the collection of peripheral blood stem cell progenitors has been shown to adequately support the management of hematological toxicities induced by the administration of high dose intensities [4] . We report in the present study the efficacy and toxicity of a chemotherapy policy based on the delivery of high dose intensities in the management of patients with carcinoma of unknown primary tumor site.
Patients and methods

Eligibility criteria
The present study was conducted at the Montpellier Cancer Center from June 1995 to December 1997. All consecutively admitted patients Patients were excluded if they had any of the following features: inclusion in subsets with specific, well-defined treatment, i.e., women with adenocarcinoma that involved only axillary lymph nodes, women with papillary serous carcinoma of the peritoneum, patients with squamous cell carcinoma that involved only cervical or inguinal lymph nodes, and patients with carcinoma that involved a single potentially resectable tumor site; progressive brain metastases despite adequate local therapy (surgery and/or radiotherapy); a history of previous malignancy with the exception of skin cancer or cervical carcinoma in situ; pregnant or lactating women; severe coexistent medical illnesses.
The study was approved by the Board for the Protection of Persons subjected to Biomedical Research of Montpellier, and patients were required to give informed consent before participation.
Pretreatment evaluation
Because of the great variability in clinical presentation, diagnostic procedures aiming at the discovery of primary tumor site varied. For the purposes of the study, patients were required to undergo at least the following procedures: thorough history and physical examination, chemistry profile including serum tumor markers prostate-specific antigen, alfafoetoprotein and human chorionic gonadotrophin, chest roentgenograms, computerized tomography (CT) scan of the chest and abdomen, and directed radiologic work-up of any symptomatic areas. Specific pathologic evaluation was additionally required for patients with light microscopic diagnosis of poorly differentiated carcinoma to exclude, if possible, other malignancies. Immunoperoxidase staining with leukocyte common antigen, cytokeratins, neuroendocrine markers (neuron-specific enolase, chromogranin and synaptophysin), and melanoma markers (S-100 protein and HMB-45) were routinely performed. For patients with adenocarcinoma, stainings for prostatespecific antigen and thyroglobulin were done.
Treatment
Chemotherapy regimens were determined according to clinical features (Table 1 ). In group A were included patients with all of the following characteristics: age less than 61 years, ECOG performance status of 0 or 1, poorly differentied adenocarcinoma or poorly differentiated carcinoma, and no evidence of brain or bone marrow involvement. The treatment plan included four sequential high-dose courses as previously described [4] . Briefly, cycle 1 included doxorubicin 75 mg/m 2 intravenously (i.v.) day 1 and cyclophosphamide 3000 mg/m 2 i.v. day 1 and day 2. Cycles 2 and 4 consisted of etoposide 200 mg/m 2 i.v. twice a day on day 1 and day 2 along with carboplatin 450 mg/m 2 by continuous i.v. infusion on day 1 and day 2. In cycle 3, doxorubicin (75 mg/m 2 i.v. day 1) was associated to cyclophosphamide 3000 mg/m 2 i.v. day 1 only. Cycles were planned for delivery every three weeks. Granulocyte-colony stimulating factor G-CSF was begun on day 5 of each cycle at a dose of 5 ug/kg/d and continued daily until peripheral blood progenitor cell (PBPC) collection after cycle 1 and a leukocyte count of 1,000/nl was reached during cycles 2-4. PBPC were harvested at the time of hematopoietic recovery after cycle 1. The apheretic product was divided into three equal fractions and infused over 15 minutes through the central venous catheter on day 4 from cycle 2-4.
Group B included patients with brain metastases provided there was no cerebral progressive disease after surgery and/or radiotherapy. Chemotherapy consisted of alternative cycles of AC (doxorubicin 50 mg/m 2 i.v. on day 1, cyclophosphamide 1000 mg/m 2 i.v. on day I) and EP (etoposide 100 mg/m 2 i.v. on day 1 to day 3, cisplatin 100 mg/m 2 i.v. on day 2). Cycles were given at two-week intervals with GM-CSF support (5 ug/kg/d) from day 4 to day 10.
Patient monitoring
Routine laboratory tests including electrolytes, creatinine, total protein, albumin, calcium, glucose, alkaline phosphatase, total and direct bilirubin, AST, ALT, and prothrombin time were evaluated on the first day of each course of chemotherapy. Complete blood cell counts were obtained three times weekly during therapy in group A, and two times weekly in group B. Toxicity was graded according to the standard World Health Organization (WHO) criteria [5] . No oral bacterial prophylaxis was administered. Hospitalization between cycles of chemotherapy was required for i.v. antibiotics when granulocytopenia-associated febrile episodes occurred, platelet or red blood cell transfusions, or management of WHO grade 3-4 non-hematological toxicities. Patients were transfused with leukocyte-free packed red blood cells and single-donor platelets to maintain hemoglobin values greater than 8 g/dl and platelet counts greater than 10,000/ ul.
No dose reduction was planned in either group. Cycles were given provided that any WHO grade 2-4 non-hematological toxicity had ended and blood counts revealed ANC > 0,500/ul, and platelet count > 100,000/ul. When patients in group A did not meet these criteria on day 21 and those in in group B on day 14, cycles were delayed until recovery.
Response assessment
All metastatic sites were completely reassessed after the fourth cycle of chemotherapy in both groups of patients. Patients with measurable disease were assigned a response category based on standard definitions [5] , Complete response required the total disappearance of all clinical and radiologically detectable disease for at least four weeks. Partial response (PR) was defined as a greater than 50% reduction in the product of the bidimensional measurements for a minimum of one month, with the appearance of no new lesions. Patients with stable disease had reductions of less than 50% or increases of less than 25% in the size of measurable lesions, with the appearance of no new lesions. Progressive disease was defined as a greater than 25% increase in tumor size or the appearance of any new lesion. Responding patients in both groups and those with stable lesions and improved symptoms could receive additional courses of AC/EP chemotherapy, according to the discretion of the treating physician.
Statistical considerations
The present study was designed using a two-step procedure. The plan was for at least 20 patients to be included in each group. Given the expected toxicity of therapy, the occurrence of progressive disease at the end of therapy in more than 10 (50%) patients in group A and 14 (66%) in group B was considered as failure. Below such progressive disease rates, 20 additional patients could be included. After completion of therapy, patients were monitored at two-month intervals until progression of disease. Follow-up evaluation was performed in all patients until the time of death. Survival curves were constructed using the method of Kaplan-Meier [6] .
Results
Patient characteristics
Sixty patients (33 males and 27 females) entered the study. Twenty patients were assigned to group A and 40 patients to group B. Patient characteristics are shown in Table 2 . As expected with selection criteria, the two groups were statistically different with respect to age, ECOG performance status and histology. Three-quarters of the patients had two or more sites of metastatic Abbreviations: PDC -poorly differentiated carcinoma; PDA -poorly differentiated adenocarcinoma.
disease. Bone, lung and liver were the dominant sites of disease in both groups. In group B, four and six patients, respectively, had evidence of brain metastases or bone marrow involvement. Overall 43 (72%) patients had measurable disease.
Delivery of scheduled chemotherapy
In group A, leukaphereses were performed following the first course of chemotherapy in 19 of 20 patients. One patient went off study after cycle 1 because of rapidly progressive disease. Of 19 patients in whom PBPC were collected, 16 (80%) achieved the scheduled program. Thus, three patients went off study before the end of intensive chemotherapy because of progressive disease. The median numbers of days between cycle 1 and cycle 2, cycle 2 and cycle 3, cycle 3 and cycle 4 were 24 (range 21-30), 23 (range 21-28) and 23 (range 21-29), respectively. None of the doses of cytotoxic agents were reduced.
In group B, the median number of alternative cycles of AC and EP was 4 (1-12). Three patients went off study after the first cycle because of toxic death (two patients) or progressive disease (one patient). Five pa- tients received more than 6 cycles of chemotherapy: 8,10 and 12 cycles were given in three, one and one patients, respectively. The median numbers of days between cycle 1 and cycle 2, cycle 2 and cycle 3, cycle 3 and cycle 4 were 15 (range 14-27), 14 (range 12-35) and 15 (range 14-22), respectively. The median intervals between subsequent cycles varied from 18 to 21 days (range 14-34).
None of the doses of cy to toxic agents were reduced.
Efficacy (Table 3) In group A, 5 of 12 patients with measurable lesions (42%; 95% confidence interval (95% CI): 22%-62%) achieved major responses to chemotherapy, including one complete response. The latter patient had a poorly differentiated carcinoma with cervical and mediastinal lymph node involvement. He relapsed six months after the end of chemotherapy. The other four patients had partial responses in the liver (two patients), in the lung (one patient) or in cervical and mediastinal lymph nodes (one patient). Both patients with initial predominant liver involvement relapsed five and seven months after the end of treatment, in the brain and the liver, respectively. They died of progressive disease 13 and 12 months after initial diagnosis, respectively. The patient with lung involvement remains free of progressive disease eight months after the end of therapy. The fourth patient who achieved a partial response in cervical and mediastinal lymph nodes relapsed in the lung four months after the end of treatment. Only one of seven patients who experienced^, no objective response to chemotherapy is alive with progressive liver disease 14 months after the end of treatment. Of eight patients with assessable disease only, six had progressive disease at the end of chemotherapy. Two patients with bone disease or pleura involvement were still free of progressive disease 26 and seven months after the end of treatment. They ultimately relapsed in Figure 1 . Survival of patients treated with high-dose chemotherapy and hematopoietic stem-cell support.
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the predominant initial site of disease and died 13 and 39 months after initial diagnosis. Only 20 patients were included since the progression rate was 65% (13 of 20 patients) at the end of therapy. The overall median survival duration of 20 patients included in group A is 11 months, with four surviving patients, one of them still clinically disease-free 12 months after the end of chemotherapy ( Figure 1 ). Forty patients were included in group B as the progression rate was 60% after the first step of the trial (12 of 20 patients). A major response was observed in 12 (39%; 95% CI: 28%-50%) of 31 patients with measurable lesions, including three complete responses. Because of an early toxic death, two patients with measurable lesions were not assessable and assigned a progressive disease. The three patients who achieved complete response had poorly differentiated carcinoma (two patients) or poorly differentiated adenocarcinoma (one patient) with initial predominant disease in cervical nodes (one patient), in lung and mediastinal nodes (one patient) and in the peritoneum (one patient). The latter patient relapsed six months after the end of chemotherapy and died of progressive disease 15 months after initial diagnosis. The other two patients remain free of progressive disease 17 and 22 months after intial diagnosis. Among nine patients who achieved a partial response, the histological type was predominantly poorly differentiated adenocarcinoma. In two patients who had been previously treated by surgery and radiotherapy for progressive brain metastases, partial responses occurred in the lung. Five patients relapsed four, five, five, six and eight months after the end of chemotherapy. The other four patients remain free of progressive disease three to eight months after the end of chemotherapy. All nine patients with assessable disease died of progressive disease only. The overall median survival duration of 40 patients included in group B is eight months, with six surviving clinically disease-free patients three to 25 months after the end of chemotherapy (Figure 2 ). Figure 2 . Survivial of patients treated with alternative cycles of AC/EP and GM-CSF support.
Toxicity
A total of 72 cycles of high-dose chemotherapy with hematopoietic support were assessable for toxicity in group A (Table 4) . No treatment-related deaths were observed. From cycle 2 to cycle 4, the median number of days with an ANC less than 500/ul increased from three to five (P = 0.01, Wilcoxon test), and the median number of days with a platelet count less than 25,000/ul increased from three to seven (P = 0.005, Wilcoxon test). Patients required between one and two platelet transfusions and between one and four units of packed red blood cells. Fever associated with neutropenia occurred in all 20 patients after cycle 1. Episodes of febrile neutropenia subsequently occurred in 26%, 41% and 50% of cycles during cycles 2, 3 and 4, respectively. No bacteriema was documented. Non-hematologic toxicity included severe (WHO grades 3 or 4) nausea /vomiting in 18 (25%) cycles, mucositis in 10 (14%) cycles and diarrhea in seven (10%) cycles. Hemorrhagic cystitis was observed in 11 (15%) cycles but never hampered the delivery of the intensive program. No cardiac, pulmonary, liver or renal toxicity was registered. The median cumulative number of hospital days related to the management of toxicity was 16 days.
In group B, 176 cycles of AC and EP were delivered in 39 patients assessable for toxicity. One patient with peritoneal adenocarcinomatosis died of major intestinal bleeding four days after the first cycle of AC. This death was related to disease progression since neither thrombopenia nor coagulopathy were observed. Two toxic deaths caused by a septic shock and a hemorrhagic shock occurred eight and 10 days after the first cycle of chemotherapy, respectively. Myelosuppression was the most common toxicity (Table 5) . Grade 3-4 neutropenia was observed in 83 (47%) courses, 24 (29%) of which required hospitalization for treatment of fever. Grade 3-4 thrombocytopenia occurred in 35 (20%) cycles. Platelet transfusions were only required after EP cycles. Grade 3-4 anemia was oberved in 51 (29%) cycles. Other significant grade 3-4 toxicities included alopecia (98% of treatment courses) and nausea/vomiting (16% of treatment courses).
Discussion
The design of a treatment plan for a patient with metastatic carcinoma of unknown primary site remains a daily challenge for physicians. However, the recent identification of treatable subsets of patients with specific clinical and pathological features has clearly improved the management of this heterogeneous disease [7] . Indeed, women with axillary lymph nodes or peritoneal carcinomatosis containing adenocarcinoma as well as patients with cervical or inguinal lymph nodes containing squamous carcinoma do require specific guidelines which may translate into prolonged survival. Unfortunately, the majority of indications for systemic therapy do not fall into one of these favorable subsets. In most cases, no chemotherapy has been firmly established as the gold standard first-line regimen [2, 7] . Response rates ranging from 0% to 50% have been reported with combination non-cisplatin-based regimens including fluorouracil and/or doxorubicin, with median survival times ranging from three to 15 months. Uncontrolled studies dealing with cisplatin-based regimens yielded similar disappointing results. Only one of the three randomized trials that have thus far compared a cisplatin versus a non-cisplatin regimen showed a survival advantage for patients treated with the cisplatin-containing chemotherapy [8] [9] [10] . Among 80 patients who were randomized to receive mitomycin C alone or in combination with epirubicin and cisplatin, a significant improvement in response rate (17% versus 50%) and median survival time (5.4 months versus 9.4 months) was observed in favor of the cisplatin-based combination treatment [10] . Whether a significant difference would have been detected with a mitomycin C/epirubicin arm remains uncertain. Nevertheless, patients with poorly differentiated neuroendocrine carcinomas and patients with poorly differentiated carcinomas or adenocarcinomas predominantly located in retroperitoneum and peripheral nodes have been reported to benefit from cisplatin-based chemotherapy [3, 11] . Among 220 patients with poorly differentiated carcinoma and poorly differentiated adenocarcinoma who were treated over a 12-year period with cisplatin-based regimens, the actuarial 10-year rate of disease-free survival was 16% [3] . In the last two decades, the delivery of increased dose-intensities of cytotoxic agents has been developed with the aim of improving the poor outcome of patients with metastatic carcinomas. Very few studies dealing with such an approach have been reported so far in patients with carcinoma of unknown primary site. Among 16 patients who received a high-dose intensity of cisplatin (200 mg/m 2 every four weeks) and etoposide, the overall response rate was 19% [12] . With the aim of assessing whether the results of conventional-dose chemotherapy could be increased by the use of higher dose-intensities, we developed a high-dose intensity policy based on increased doses of chemotherapy per cycle or reduced time intervals between cycles. Treatment regimens were determined according to clinical features. Twenty patients with rather 'good-risk' characteristics (young age, good performance status, absence of brain and bone marrow involvement and potentially chemo-sensitive histological types) were treated with a four-step highdose sequential chemotherapy with hematopoietic progenitor-cell support. In the present series we confirmed the feasibility we previously reported [4] . Indeed, such an approach results in a significant increase in doseintensity while providing a noteworthy but manageable toxicity. Unfortunately, the median overall survival of 11 months was not clearly different from that observed after conventional-dose chemotherapy. Similar disappointing results were seen in the group of patients in whom reduced intervals between cycles of conventional-dose chemotherapy were planned since the overall median survival was eight months. Moreover, toxicity was sustained and two toxic deaths were observed. Obviously, the direct comparison in the outcome of patients assigned to treatment groups is not valid since their clinical characteristics were clearly distinct.
From our point of view, there is no argument in favor of further studying the impact of high dose-intensity regimens in the management of carcinoma of unknown primary site. The availability of several new cytotoxic agents with broad-spectrum clinical activity (such as taxoids, tecans and gemcitabine) should be the rationale for prospective trials. A median survival of 13.4 months was recently reported with a combination of paclitaxel, carboplatin and etoposide in a series of 55 patients [13] . It is to be hoped that these preliminary results comprise the first step toward fresh progress in the management of patients with carcinoma with unknown primary site.
